Laminin: Difference between revisions
Michal Harel (talk | contribs) No edit summary |
Michal Harel (talk | contribs) No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='5xau' size='340' side='right' caption='Human lamini integrin binding domain. Subunit α-5 (grey), subunit β-1 (green), subunit γ-1 (yellow) (PDB code [[5xau]])' scene=''> | |||
<StructureSection load='5xau' size='340' side='right' caption=' | |||
== Function == | == Function == | ||
| Line 10: | Line 9: | ||
== Relevance == | == Relevance == | ||
Serum concentration of laminin is increased in patients with inflammatory bowel disease hence can be used as a marker for sustained inflammation<ref>PMID:14600124</ref>. Laminin was found to have an anti-amyloidogenic effect and | Serum concentration of laminin is increased in patients with inflammatory bowel disease hence can be used as a marker for sustained inflammation<ref>PMID:14600124</ref>. Laminin was found to have an anti-amyloidogenic effect and γmay be of therapeutic value in Alzheimer Disease<ref>PMID:11323745</ref>. Laminin-111 was found to be a highly therpeutic agent in mice with Duchenne muscular dystrophy<ref>PMID:19416897</ref>. | ||
== Structural highlights == | == Structural highlights == | ||